BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 38519482)

  • 1. Activating Mutations of ESR1, BRCA1 and CYP19 Aromatase Genes Confer Tumor Response in Breast Cancers Treated with Antiestrogens.
    Suba Z
    Recent Pat Anticancer Drug Discov; 2017; 12(2):136-147. PubMed ID: 28245776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteomic profiling reveals that ESR1 mutations enhance cyclin-dependent kinase signaling.
    De Marchi T; Lai CF; Simmons GM; Goldsbrough I; Harrod A; Lam T; Buluwela L; Kjellström S; Brueffer C; Saal LH; Malmström J; Ali S; Niméus E
    Sci Rep; 2024 Mar; 14(1):6873. PubMed ID: 38519482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic modelling of the ESR1 Y537S mutation for evaluating function and new therapeutic approaches for metastatic breast cancer.
    Harrod A; Fulton J; Nguyen VTM; Periyasamy M; Ramos-Garcia L; Lai CF; Metodieva G; de Giorgio A; Williams RL; Santos DB; Gomez PJ; Lin ML; Metodiev MV; Stebbing J; Castellano L; Magnani L; Coombes RC; Buluwela L; Ali S
    Oncogene; 2017 Apr; 36(16):2286-2296. PubMed ID: 27748765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longitudinal Molecular Imaging of Progesterone Receptor Reveals Early Differential Response to Endocrine Therapy in Breast Cancer with an Activating
    Kumar M; Salem K; Jeffery JJ; Yan Y; Mahajan AM; Fowler AM
    J Nucl Med; 2021 Apr; 62(4):500-506. PubMed ID: 32859700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prevalence of estrogen receptor-1 mutation in advanced breast cancer: The estrogen receptor one study (EROS1).
    Najim O; Huizing M; Papadimitriou K; Trinh XB; Pauwels P; Goethals S; Zwaenepoel K; Peterson K; Weyler J; Altintas S; van Dam P; Tjalma W
    Cancer Treat Res Commun; 2019; 19():100123. PubMed ID: 30826563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models.
    Bahreini A; Li Z; Wang P; Levine KM; Tasdemir N; Cao L; Weir HM; Puhalla SL; Davidson NE; Stern AM; Chu D; Park BH; Lee AV; Oesterreich S
    Breast Cancer Res; 2017 May; 19(1):60. PubMed ID: 28535794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer.
    Brett JO; Spring LM; Bardia A; Wander SA
    Breast Cancer Res; 2021 Aug; 23(1):85. PubMed ID: 34392831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genome engineering for estrogen receptor mutations reveals differential responses to anti-estrogens and new prognostic gene signatures for breast cancer.
    Harrod A; Lai CF; Goldsbrough I; Simmons GM; Oppermans N; Santos DB; Győrffy B; Allsopp RC; Toghill BJ; Balachandran K; Lawson M; Morrow CJ; Surakala M; Carnevalli LS; Zhang P; Guttery DS; Shaw JA; Coombes RC; Buluwela L; Ali S
    Oncogene; 2022 Oct; 41(44):4905-4915. PubMed ID: 36198774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples.
    Ianevski A; Giri AK; Aittokallio T
    Nucleic Acids Res; 2022 Jul; 50(W1):W739-W743. PubMed ID: 35580060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ESR1 mutant breast cancers show elevated basal cytokeratins and immune activation.
    Li Z; McGinn O; Wu Y; Bahreini A; Priedigkeit NM; Ding K; Onkar S; Lampenfeld C; Sartorius CA; Miller L; Rosenzweig M; Cohen O; Wagle N; Richer JK; Muller WJ; Buluwela L; Ali S; Bruno TC; Vignali DAA; Fang Y; Zhu L; Tseng GC; Gertz J; Atkinson JM; Lee AV; Oesterreich S
    Nat Commun; 2022 Apr; 13(1):2011. PubMed ID: 35440136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hotspot ESR1 Mutations Are Multimodal and Contextual Modulators of Breast Cancer Metastasis.
    Li Z; Wu Y; Yates ME; Tasdemir N; Bahreini A; Chen J; Levine KM; Priedigkeit NM; Nasrazadani A; Ali S; Buluwela L; Arnesen S; Gertz J; Richer JK; Troness B; El-Ashry D; Zhang Q; Gerratana L; Zhang Y; Cristofanilli M; Montanez MA; Sundd P; Wallace CT; Watkins SC; Fumagalli C; Guerini-Rocco E; Zhu L; Tseng GC; Wagle N; Carroll JS; Jank P; Denkert C; Karsten MM; Blohmer JU; Park BH; Lucas PC; Atkinson JM; Lee AV; Oesterreich S
    Cancer Res; 2022 Apr; 82(7):1321-1339. PubMed ID: 35078818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteogenomic discovery of sORF-encoded peptides associated with bacterial virulence in Yersinia pestis.
    Cao S; Liu X; Huang Y; Yan Y; Zhou C; Shao C; Yang R; Zhu W; Du Z; Jia C
    Commun Biol; 2021 Nov; 4(1):1248. PubMed ID: 34728737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preexisting Somatic Mutations of Estrogen Receptor Alpha (
    Dahlgren M; George AM; Brueffer C; Gladchuk S; Chen Y; Vallon-Christersson J; Hegardt C; Häkkinen J; Rydén L; Malmberg M; Larsson C; Gruvberger-Saal SK; Ehinger A; Loman N; Borg Å; Saal LH
    JNCI Cancer Spectr; 2021 Apr; 5(2):. PubMed ID: 33937624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hormonal modulation of ESR1 mutant metastasis.
    Gu G; Tian L; Herzog SK; Rechoum Y; Gelsomino L; Gao M; Du L; Kim JA; Dustin D; Lo HC; Beyer AR; Edwards DG; Gonzalez T; Tsimelzon A; Huang HJ; Fernandez NM; Grimm SL; Hilsenbeck SG; Liu D; Xu J; Alaniz A; Li S; Mills GB; Janku F; Kittler R; Zhang XH; Coarfa C; Foulds CE; Symmans WF; Andò S; Fuqua SAW
    Oncogene; 2021 Feb; 40(5):997-1011. PubMed ID: 33323970
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.